Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023
{{output}}
Background: The Chinese biosimilar industry has demonstrated rapid growth in recent years. Limited evidence is available about biosimilar uptake at the national level. This study aimed to assess biosimilar uptake in the case of t... ...
